Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 4/20 | 0.56 |
| ▸ | ADRA2B | P18089 | 4/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6837642 | 1.00 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CNPC1MEN1 | |
| SCHEMBL6833398 | 1.00 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CNPC1MEN1 | |
| SCHEMBL6837405 | 0.99 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CNPC1MEN1 | |
| SCHEMBL6837532 | 0.92 | ADRA2A (0.52) | ADRA2AADRA2BADRA2CNPC1MEN1 | |
| SCHEMBL6833377 | 0.87 | ADRA2A (0.55) | ADRA2AADRA2BADRA2CNPC1KDM4E | |
| SCHEMBL6833406 | 0.86 | ADRA2A (0.56) | ADRA2AADRA2BADRA2CNPC1MEN1 | |
| SCHEMBL6837591 | 0.85 | MEN1 (0.48) | ADRA2AADRA2BADRA2CNPC1MEN1 | |
| SCHEMBL6837851 | 0.85 | MEN1 (0.48) | ADRA2AADRA2BADRA2CNPC1MEN1 | |
| SCHEMBL6837984 | 0.85 | MEN1 (0.48) | ADRA2AADRA2BADRA2CNPC1MEN1 | |
| SCHEMBL6837639 | 0.85 | MEN1 (0.48) | ADRA2AADRA2BADRA2CNPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | ADRA2A 1965/4885ADRA2B 1631/4885ADRA2C 1669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.